1,677 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Tolleson Wealth Management Inc.

Tolleson Wealth Management Inc. bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, Holdings Channel reports. The fund bought 1,677 shares of the company’s stock, valued at approximately $243,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $32,000. Finally, Conquis Financial LLC purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $33,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.2%

NYSE:JNJ opened at $151.37 on Friday. The company has a fifty day moving average of $156.27 and a 200 day moving average of $153.90. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $364.20 billion, a P/E ratio of 22.76, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio is currently 57.84%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Barclays cut their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Finally, Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.